We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic lung adenocarcinoma is a type of lung cancer that has spread beyond the lungs to other parts of the body. It is characterized by the absence of TTF-1, a protein that can indicate the presence of certain lung cancers, and may present symptoms such as persistent cough, chest pain, and difficulty breathing.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.